Zentalis Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 9, 2026, disclosing financial results, operational updates, and risk factors for the quarter.

Key Highlights

  • Share count: As of November 4, 2026, the company had 98,265,863 shares of common stock, $0.001 par value per share, outstanding.
  • Filer classification: The company reported it is a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
  • Primary program: The filing identifies azenosertib (ZN-c3) as the company's prioritized asset, with the company disclosing plans for multiple ongoing and planned clinical studies.
  • Key trials referenced: The filing names the ASPENOVA Phase 3 confirmatory trial in Cyclin E1-positive platinum-resistant ovarian cancer patients and the MUIR Phase 1b study evaluating azenosertib in combination with chemotherapy regimens.
  • DENALI Part 2: According to the filing, DENALI Part 2, if successful, could "support an accelerated approval for azenosertib," as stated in the company's forward-looking disclosures.
  • Exchange listing: Common stock is listed on NASDAQ:ZNTL on The Nasdaq Global Market.
  • Shell company status: The registrant indicated it is not a shell company as defined under Rule 12b-2 of the Exchange Act.

Zentalis Pharmaceuticals' Third-Quarter 2026 Filing: Azenosertib Trials and Company Status

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), headquartered at 10275 Science Center Dr., Suite 200, San Diego, California 92121, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing covers the company's financial statements, management's discussion and analysis, and an extensive set of risk factors for the period. As of November 4, 2026, the company reported 98,265,863 shares of common stock outstanding at a par value of $0.001 per share.

According to the filing, the company has prioritized azenosertib (ZN-c3) as its lead program, describing potential for the asset to be "first-in-class and best-in-class" - a characterization the company presents as forward-looking and subject to its cautionary language. The filing identifies several active and planned clinical programs: the ASPENOVA Phase 3 confirmatory trial of monotherapy azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer patients, the MUIR Phase 1b study evaluating azenosertib in combination with chemotherapy regimens, and the DENALI Part 2 study, which the company disclosed could potentially support an accelerated approval for azenosertib if successful. The filing also references a potential clinical study of azenosertib in triple-negative breast cancer.

The company disclosed plans relating to a companion diagnostic intended to identify patients with Cyclin E1-positive platinum-resistant ovarian cancer, as well as plans to evaluate additional strategic opportunities and develop azenosertib in combination with other therapies. The filing noted the company's at-the-market offering program as a potential source of additional capital. All forward-looking statements in the filing are the company's own and are subject to its cautionary language, including references to the global macroeconomic environment and increased inflation levels as factors that could affect results.

What Was Disclosed

Zentalis Pharmaceuticals filed its Form 10-Q for the quarter ended September 30, 2026, reporting 98,265,863 shares outstanding as of November 4, 2026, its non-accelerated and smaller reporting company status, and details on azenosertib clinical programs including ASPENOVA, MUIR, and DENALI Part 2.